BUKIT JALIL, February 3 — Cervical cancer, the fourth most common cancer among women in Malaysia, remains a pressing health challenge, with 1,740 new cases reported annually. However, the Human Papillomavirus (HPV) vaccine is reshaping the landscape of cervical cancer prevention. Dr Nur Adila Mokhtar, Consultant Clinical Oncologist at OncoCare Cancer Centre Malaysia, emphasised that early vaccination can reduce cervical cancer rates by up to 90%, offering long-lasting protection when administered between ages 11 and 12.
Dr Nur Adila also highlighted the importance of combining vaccination with regular cervical cancer screenings, such as Pap smears and HPV testing, to detect and prevent abnormalities before they develop into cancer. Recent advancements, including the 9-valent HPV vaccine and self-collection kits for HPV testing, aim to improve accessibility and effectiveness, particularly in underserved areas. By prioritising education, early intervention, and collaboration, Malaysia is paving the way toward reducing cervical cancer rates and safeguarding women’s health for generations.
